Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations ...

Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com .

Reports Q4 revenue $0, consensus $2.1M. As of December 31, 2024, Spyre had cash, cash equivalents, and marketable securities of $603.1M. “In 2024, we initiated first-in-human studies for three ...

WALTHAM, Mass., March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing ...